Akers Biosciences, Inc. Independent Sales Representative Agreements - PIFA
April 12 2018 - 6:00AM
RNS Non-Regulatory
TIDMAKR
Akers Biosciences, Inc.
12 April 2018
April 12, 2018
Akers Biosciences, Inc.
Akers Bio Expands Outsourced US Distribution Capabilities for
Heparin PF4 Rapid Test
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, announces the engagement of two leading Independent
Sales Representative (ISR) organizations to increase US sales and
marketing capabilities for the Company's rapid test for
heparin-induced thrombocytopenia (HIT).
The agreements with Opto-Systems, Inc. ("Opto-Systems") and
Herzog Surgical, Inc. ("Herzog Surgical") are in line with Akers
Bio's strategy to create platelet factor 4 awareness amongst
surgeons - principally orthopaedic and cardiac surgeons - and to
expand the utilization of the Company's point-of-care PIFA
Heparin/PF4 Rapid Assay product platform.
Opto-Systems, based in Newtown, PA, has a 39-year history in
medical device sales and distribution, with expertise in surgical
specialties, including orthopaedic surgeons. Opto-Systems has a
team of highly trained representatives based in Delaware, New
Jersey, New York, and Pennsylvania, calling on physicians,
hospitals and medical offices. Following a period of training in
the sales and associated support for PIFA Heparin/PF4 Rapid Assay
products, Opto-Systems will broaden Akers Bio's US sales coverage
in the northeast with a specific focus on the clinical end-users of
the Company's rapid test.
Herzog Surgical, based in Sacramento, CA, has a 30-year track
record serving the healthcare community as a distributor of
specialized products with applications in all areas of medicine.
Herzog Surgical's sales team members have on average over 13 years
of tenure. They bring significant relationships with cardiac
surgeons as well as with hospitals and Integrated Delivery Networks
within California and northern Nevada. Following a period of
training in the sales and associated support for PIFA Heparin/PF4
Rapid Assay products, Herzog Surgical will broaden Akers Bio's US
sales coverage across northern Nevada and the entire state of
California, also with a specific focus on the clinical end-users of
the Company's rapid test.
John J. Gormally, Chief Executive Officer of Akers Bio,
commented: "The development of Akers Bio's Independent Sales
Representative organization is a key component of our strategy to
increase awareness and sales of PIFA Heparin/PF4 Rapid Assay
products in the US. It represents the third wave of our
commercialization strategy which included value captured in price,
a strategy to target Integrated Delivery Networks and now, a
strategy to influence the clinical pathway by educating the
clinical end-users on the critical medical benefits of adopting
this rapid test for heparin platelet factor 4 antibodies.
"We are thrilled to be working with Opto-Systems and Herzog
Surgical whose respective specialized capabilities will bolster our
sales efforts and allow our test to gain substantial additional
regional coverage at a clinical level. We are looking forward to
working with them - and other ISR organizations with whom we expect
to engage in due course - to effect real change in the clinical
pathway for the diagnosis of HIT."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9700
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGMDRZFGRZG
(END) Dow Jones Newswires
April 12, 2018 07:00 ET (11:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024